Abstracts tagged "interstitial lung disease and rheumatoid arthritis (RA)"

Abstract Number: 963 • 2015 ACR/ARHP Annual Meeting
Ectopic Lymphoid Tissue in the Lung Is Associated with Serum Rheumatoid Arthritis-Related Autoantibodies Even in Absence of Clinically Apparent Rheumatoid Arthritis
Lindsay E. Brown¹, M. Kristen Demoruelle², Mark C. Parish³, Marie L. Feser², Peter B. Sachs⁴, David E. Heinz⁵, Carlyne D. Cool¹ and Kevin D. Deane⁶, ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴Department of Radiology, University of Colorado School of Medicine, Aurora, CO, ⁵Pathology, University of Colorado School of Medicine, Aurora, CO, ⁶Division of Rheumatology, U Colo Denver, Aurora, CO
Background/Purpose: Lung disease has been associated with elevations of RA and Sjogren's-related autoantibodies (Abs), even in the absence of extrathoracic features of these diseases (Fischer…
Abstract Number: 1337 • 2015 ACR/ARHP Annual Meeting
Pulmonary Computed Tomography Changes in Patients with Rheumatoid Arthritis
Alexandra Balbir-Gurman¹, Ludmila Guralnik², Mordehai Yigla³, Yolanda Braun-Moscovici⁴, Anna Astrahan⁵ and Emilia Hardak⁶, ¹B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel, ²Department of Diagnostic Imaging, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel, ³Division of Pulmonary Medicine, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel, ⁴B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁵Rappaport Faculty of Medicine-Technion, Israeli Institute of Technology, Haifa, Israel, ⁶Pulmonary Institute, Rambam Health Care Campus; Rappaport Faculty of Medicine-Technion, Israeli Institute of Technology, Haifa, Israel
Background/Purpose: Lung involvement in RA it is often diagnosed in advanced stage. Chest CT is the main modality for assessment of ILD. To analyze chest…
Abstract Number: 1599 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) Patients in High Resolutional CT (HRCT) and Titer of Anti Citrullinated Peptide Antibodies (anti-CCP2)
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. And to analyze whether high resolutional CT (HRCT) and anti…
Abstract Number: 2457 • 2014 ACR/ARHP Annual Meeting
Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Hiroshi Furukawa¹, Shomi Oka¹, Kota Shimada², Akiko Komiya¹, Naoshi Fukui¹, Naoyuki Tsuchiya³ and Shigeto Tohma¹, ¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ³Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD) that influences the prognosis of the disease.…
Abstract Number: 1907 • 2014 ACR/ARHP Annual Meeting
Clinical Evaluation of Anti-Aminoacyl tRNA Synthase Antibodies in Rheumatoid Arthritis Patients
Masakazu Matsushita¹, Ken Yamaji¹, Naoto Tamura² and Yoshinari Takasaki³, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-Jo-1 is an autoantibody that is specifically detected in the blood sera of patients with polymyositis/dermatomyositis (PM/DM). The corresponding antigen is known to be…
Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting
Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis
Muhammad Imran¹, Shanley O'brien², Mark Hamblin³ and Mehrdad Maz⁴, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, Kansas University Medical Center, Kansas city, MO, ³Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
Abstract Number: 1377 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibody Titers and the Prevalence of Interstitial Lung Disease in Patients with and without Rheumatoid Arthritis
Chase Correia¹, Melissa R. Bussey², Brittany Panico¹, Rong Guo³ and Rochella A. Ostrowski⁴, ¹Internal Medicine, Loyola University Medical Center, Chicago, IL, ²Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ³Loyola University Medical Center, Chicago, IL, ⁴Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Rheumatoid arthritis (RA) is a multisystem inflammatory disease characterized by a symmetric, destructive polyarthritis. Interstitial lung disease (ILD) is an extra-articular manifestation that…
Abstract Number: 1366 • 2014 ACR/ARHP Annual Meeting
Outcomes of Interstitial Lung Disease Associated with Rheumatoid Arthritis in High Volume Referral Centers
Megan Krause¹, Amish Dave², Cynthia S. Crowson³, Arun K. Chandran¹, C. John Michet III¹, Paul F. Dellaripa⁴ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To describe the characteristics and morbidity and mortality impact of interstitial lung disease in rheumatoid arthritis (RA). Methods: A retrospective review was performed at…
Abstract Number: 472 • 2014 ACR/ARHP Annual Meeting
Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake³ and Katsutoshi Ando⁴, ¹[email protected], Kameda Medical Center, Kamogawa City, Japan, ²[email protected], Kameda Medical Center, Kamogawa-city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ⁴Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan
Background/Purpose : Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].